Rolapitant
- Generic Name
- Rolapitant
- Brand Names
- Varubi
- Drug Type
- Small Molecule
- Chemical Formula
- C25H26F6N2O2
- CAS Number
- 552292-08-7
- Unique Ingredient Identifier
- NLE429IZUC
- Background
Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in ...
- Indication
This drug is indicated in adults in combination with other antiemetics for the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy.
- Associated Conditions
- Delayed chemotherapy-induced nausea and vomiting
- Associated Therapies
- -
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- Costantine Albany
- Registration Number
- NCT03960151
Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
- Conditions
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Duke University
- Target Recruit Count
- 48
- Registration Number
- NCT02991456
- Locations
- πΊπΈ
The Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT02434861
- Locations
- πΊπΈ
Parexel Early Phase Unit, Baltimor, Maryland, United States
A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02382666
- Locations
- πΊπΈ
Parexel, Baltimore, Maryland, United States
Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 1369
- Registration Number
- NCT01500226
- Locations
- πΊπΈ
TESARO Inc, Waltham, Massachusetts, United States
Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 555
- Registration Number
- NCT01500213
- Locations
- πΊπΈ
TESARO Inc, Waltham, Massachusetts, United States
Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 532
- Registration Number
- NCT01499849
- Locations
- πΊπΈ
TESARO Inc, Waltham, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.